

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL	
OMB Number:	3235-0101
Expires:	June 30, 2020
Estimated average burden hours per response .....	1.00

**FORM 144**

**NOTICE OF PROPOSED SALE OF SECURITIES  
PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933**

**ATTENTION:** *Transmit for filing 3 copies of this form concurrently with either placing an order with a broker to execute sale or executing a sale directly with a market maker.*

SEC USE ONLY
DOCUMENT SEQUENCE NO.
CUSIP NUMBER
WORK LOCATION

1 (a) NAME OF ISSUER (Please type or print)  Denali Therapeutics Inc.		(b) IRS IDENT. NO.  46-3872213	(c) S.E.C. FILE NO.  001-38311
1 (d) ADDRESS OF ISSUER  161 Oyster Point Blvd.	STREET  South San Francisco	CITY  CA	STATE  94080
		(e) TELEPHONE NO.	
		AREA CODE 650	NUMBER 866-8548
2 (a) NAME OF PERSON FOR WHOSE ACCOUNT THE SECURITIES ARE TO BE SOLD  Neuro Line Partners, L.P.		(b) RELATIONSHIP TO ISSUER  More than 10% Shareholder (1)	(c) ADDRESS STREET  201 Main Street, Suite 1900
		CITY  Fort Worth	STATE  TX
		ZIP CODE  76101	

**INSTRUCTION:** *The person filing this notice should contact the issuer to obtain the I.R.S. Identification Number and the S.E.C. File Number.*

3(a) Title of the Class of Securities To Be Sold	(b) Name and Address of Each Broker Through Whom the Securities are to be Offered Or Each Market Maker who is Acquiring the Securities	SEC USE ONLY	(c) Number of Shares or Other Units To Be Sold  (See instr. 3(c))	(d) Aggregate Market Value  (See instr. 3(d))	(e) Number of Shares or Other Units Outstanding  (See instr. 3(e))	(f) Approximate Date of Sale  (See instr. 3(f)) (MO. DAY YR.)	(g) Name Of Each Securities Exchange  (See instr. 3(g))
		Broker-Dealer File Number					
Common Stock (\$0.01 par value)	Goldman Sachs & Co. LLC 200 West Street New York, NY 10282		82,578	\$1,965,356.40	105,628,182	06/29/2020	NASDAQ Global Select Market

**INSTRUCTIONS:**

- Name of issuer
  - Issuer's I.R.S. Identification Number
  - Issuer's S.E.C. file number, if any
  - Issuer's address, including zip code
  - Issuer's telephone number, including area code
- Name of person for whose account the securities are to be sold
  - Such person's relationship to the issuer (e.g., officer, director, 10% stockholder, or member of immediate family of any of the foregoing)
  - Such person's address, including zip code
- Title of the class of securities to sold
  - Name and address of each broker through whom the securities are intended to be sold
  - Number of shares or other units to be sold (if debt securities, give the aggregate face amount)
  - Aggregate market value of the securities to be sold as of a specified date within 10 days prior to the filing of this notice
  - Number of shares or other units of the class outstanding, or if debt securities the fact amount thereof outstanding, as shown by the most recent report or statement published by the issuer
  - Approximate date on which the securities are to be sold
  - Name of each securities exchange, if any, on which the securities are intended to be s

**Potential persons who are to respond to the collection of information contained in this form are not  
required to respond unless the form displays a currently valid OMB control number.**

SEC 1147 (02-08)

**TABLE I — SECURITIES TO BE SOLD**

*Furnish the following information with respect to the acquisition of the securities to be sold  
and with respect to the payment of all or any part of the purchase price or other consideration therefor:*

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired (If gift, also give date donor acquired)	Amount of Securities Acquired	Date of Payment	Nature of Payment
Common Stock, par value \$0.01 per share	Conversion of Series A-1, Series A-2, and Series B-1 Convertible Preferred Stock upon closing of initial public offering on December 12, 2017	Conversion of Series A-1, Series A-2 and Series B-1 Convertible Preferred Stock upon closing of initial public offering	Denali Therapeutics, Inc.	575,958	Same as date of acquisition	Upon conversion of Convertible Preferred Stock

**INSTRUCTIONS:** If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

**TABLE II — SECURITIES SOLD DURING THE PAST THREE MONTHS**

*Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.*

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
AKDL, L.P. 201 Main Street, Suite 1900 Fort Worth, TX 76102	Common Stock	06/05/2020	1,922,855	\$49,513,516.25
Neuro Line Partners, L.P. 201 Main Street, Suite 1900 Fort Worth, TX 76102	Common Stock	6/19/2020	144,920	\$3,556,496.21
Neuro Line Partners, L.P. 201 Main Street, Suite 1900 Fort Worth, TX 76102	Common Stock	6/22/2020	90,056	\$2,231,893.87
Neuro Line Partners, L.P. 201 Main Street, Suite 1900 Fort Worth, TX 76102	Common Stock	6/23/2020	20,024	\$515,968.42
Neuro Line Partners, L.P. 201 Main Street, Suite 1900 Fort Worth, TX 76102	Common Stock	6/26/2020	122,077	\$2,922,083.90

**REMARKS:**

(1) Neuro Line Partners, L.P. (“Neuro Line”) directly holds the shares of the Denali Therapeutics Inc. (the “Issuer”) being sold. Douglas K. Bratton ultimately controls Neuro Line and AKDL, L.P. (“AKDL”) and, collectively with his affiliates, owns 10% or more of the outstanding common stock of the Issuer. AKDL holds 13,644,881 shares of common stock of the Issuer. Neuro Line and AKDL are each ultimately controlled by Mr. Bratton, but AKDL is not currently selling.

**INSTRUCTIONS:**

See the definition of “person” in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (c) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

06/29/2020

DATE OF NOTICE

DATE OF PLAN ADOPTION OR GIVING OF INSTRUCTION,  
IF RELYING ON RULE 10B5-1

**ATTENTION:**

*The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.*

/s/ John S. Cochran

**Neuro Line Partners, L.P.**

**By: Bratton Capital Management, L.P., its general partner**

**By: Bratton Capital, Inc., its general partner**

*The notice shall be signed by the person for whose account the securities are to be sold. At least one copy of the notice shall be manually signed. Any copies not manually signed shall bear typed or printed signatures.*

**ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)**

SEC 1147 (02-08)